Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neutropenia 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Infections 1 Carcinoma, Hepatocellular 1

Interventions

Sorafenib 121 Nivolumab 36 pembrolizumab 32 Bevacizumab 28 lenvatinib 27 Doxorubicin 23 Radiosurgery 21 Radiofrequency Ablation 20 Oxaliplatin 20 Hepatectomy 18 Fluorouracil 15 Capecitabine 15 Magnetic Resonance Spectroscopy 14 atezolizumab 13 Leucovorin 13 Cisplatin 13 Gemcitabine 11 Erlotinib Hydrochloride 11 tislelizumab 9 Sirolimus 9 Radiotherapy 9 Irinotecan 9 Ipilimumab 9 cabozantinib 8 Liver Transplantation 8 regorafenib 7 Ramucirumab 7 Folfox protocol 7 Embolization, Therapeutic 7 sintilimab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma, Hepatocellular × Anidulafungin × Clear all

NCT01686607 2024-10-21

MYCOS

Astellas Pharma Inc

40,110 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡